Sign In
Buy SENS
$5.03
-0.0400 (-0.789%)
At Close: Jul 31, 2026
Senseonics' (SENS) Deal With Mercy to Drive Eversense CGM Sales
09:56am, Wednesday, 15'th May 2024
Senseonics Holdings (SENS) collaborates with Mercy to bring its Eversense CGM to a healthcare system that is likely to drive its adoption.
Senseonics Holdings, Inc. (SENS) Q1 2024 Earnings Call Transcript
07:52pm, Monday, 13'th May 2024
Start Time: 16:30 January 1, 0000 5:11 PM ET Senseonics Holdings, Inc. (NYSE:SENS ) Q1 2024 Earnings Conference Call May 13, 2024, 16:30 AM ET Company Participants Tim Goodnow - President and CEO Rick
Senseonics Holdings, Inc. Reports First Quarter 2024 Financial Results
04:05pm, Monday, 13'th May 2024
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos
Senseonics and Mercy Collaborate to Improve Diabetes Population Health Management
04:04pm, Monday, 13'th May 2024
GERMANTOWN, Md. & CHESTERFIELD, Mo.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantab
Senseonics Partners with Rimidi to Develop Innovative Diabetes Solution
04:05pm, Thursday, 09'th May 2024
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos
Senseonics Holdings, Inc. to Participate in Upcoming Conferences
08:05am, Thursday, 02'nd May 2024
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos
Eversense® CGM System Receives iCGM Designation by the US FDA
07:00am, Tuesday, 30'th Apr 2024
GERMANTOWN, Md. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantabl
SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS
07:00am, Tuesday, 12'th Mar 2024
Eligible individuals in the U.S. will pay $99 out of pocket for each 6-month CGM system, offering each year of continuous glucose monitoring for just $200* PARSIPPANY, N.J. , March 12, 2024 /PRNewswir
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos
Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference
08:05am, Wednesday, 06'th Mar 2024
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos
Senseonics Holdings, Inc. (SENS) Q4 2023 Earnings Call Transcript
07:34pm, Thursday, 29'th Feb 2024
Senseonics Holdings, Inc. (NYSE:SENS) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET
Senseonics Holdings (SENS) Reports Q4 Loss, Tops Revenue Estimates
07:31pm, Thursday, 29'th Feb 2024
Senseonics Holdings (SENS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.01 per share a year ago.
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
04:05pm, Thursday, 29'th Feb 2024
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos
